ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1621

Analysis of Hospitalizations of Adult Patients with Kawasaki’s Disease: A United States Population Based Study

Ufuoma Mamoh1, Soziema Salia1, Joan Morny2, Jesse Odion3, Elem Ewuru4, Precious Onobraigho5, Eugene Omoike5, Oyidia Ijioma6, Osaruese Ezomo7 and Ehizogie Edigin8, 1Medstar Union Memorial Hospital, Baltimore, MD, 2Piedmont Athens Regional Medical Center, Athens, GA, 3Royal Devon University Healthcare NHS Foundation Trust, Barnstaple, United Kingdom, 4Acute and Emergency Care United Kingdom Medway Maritime Hospital, Gillingham, 5College of Medicine, University of Benin, Benin, Nigeria, 6Department of Clinical Psychiatry, University of South Wales, Wales, United Kingdom, 7Department of Gastroenterology, Spire Manchester Hospital, Manchester, United Kingdom, 8The University of Texas Health Science Center, houston, TX

Meeting: ACR Convergence 2024

Keywords: autoimmune diseases, Autoinflammatory diseases, Heart disease, Vasculitis

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Sunday, November 17, 2024

Title: Vasculitis – Non-ANCA-Associated & Related Disorders Poster II

Session Type: Poster Session B

Session Time: 10:30AM-12:30PM

Background/Purpose: Kawasaki disease (KD) is a systemic vasculitis, typically affecting young children, and is the leading cause of acquired heart disease in children in developed countries. Adult-onset KD is rare and often misdiagnosed or diagnosed late [1]. There is a scarcity of national population studies on hospitalizations of adult patients with KD. We aim to study reasons for hospitalization, baseline demographic characteristics, and outcomes of hospitalizations of adult patients with KD.

Methods: Data were abstracted from the National Inpatient Sample (NIS) 2016 and 2017 combined database. NIS is a nationally representative approximate 20-percent stratified sample of all discharges from U.S community hospitals, excluding rehabilitation and long-term acute care hospitals. The numbers in the databases are weighted to optimize national estimates. Each hospitalization in the NIS has only 1 principal diagnosis and can have up to 39 secondary diagnoses. The principal diagnosis is the main reason for hospitalization. Any diagnosis other than the principal, is a secondary diagnosis. The NIS was searched for hospitalizations for adult patients aged ≥ 18 years with a diagnosis of KD as the principal or secondary diagnosis using International Classification of Diseases, tenth revision (ICD-10) code “M303”. Baseline demographic characteristics and outcomes of these hospitalizations were recorded. Analyses were performed using STATA,16. We used a “rank” order command in STATA to arrange the most common reasons for hospitalization in descending order of frequency based on ICD-10 code organ system categories and the most specific ICD-10 code principal discharge diagnosis. 

Results:  There were over 70 million discharges included in the 2016 and 2017 combined NIS database. We found 11,355 hospitalizations with either principal or secondary diagnosis of KD. Out of these, 990 hospitalizations were for adult patients. Adult KD hospitalizations were mostly males (58%), mean age of 41 years, whites (58.9%), privately insured (43.9%), and presented to teaching hospitals (71.2%). Inpatient mortality occurred in 2%, mean hospital length of stay was 5.5 days, and mean total hospital charges was 74,816 U.S dollars. Cardiovascular (CV) diseases were the most common reason for hospitalization by ICD-10 code category; 290 (29.3%) (Table 1).  Non-ST elevation myocardial infarction (NSTEMI) was the most common specific reason for hospitalization; 75 (7.6%) ( Table 2) , followed by sepsis, unspecified organism 50 (5.1%), and KD 50 (5.1%). 

Conclusion: CV diseases were the most common reason for hospitalization by ICD-10 code category in adult patients with KD. NSTEMI, sepsis, and KD were the top 3 most common specific reasons for hospitalization. Optimal management of KD and associated CV comorbidities, early detection, and management of infections in the outpatient setting are important in reducing hospitalizations of these patients.

Supporting image 1

Table 1: ICD_10 code organ system categories for hospitalizations of patients with Kawasaki’s disease

Supporting image 2

Table 2: Most common specific reasons for hospitalizations of patients with Kawasaki’s disease


Disclosures: U. Mamoh: None; S. Salia: None; J. Morny: None; J. Odion: None; E. Ewuru: None; P. Onobraigho: None; E. Omoike: None; O. Ijioma: None; O. Ezomo: None; E. Edigin: None.

To cite this abstract in AMA style:

Mamoh U, Salia S, Morny J, Odion J, Ewuru E, Onobraigho P, Omoike E, Ijioma O, Ezomo O, Edigin E. Analysis of Hospitalizations of Adult Patients with Kawasaki’s Disease: A United States Population Based Study [abstract]. Arthritis Rheumatol. 2024; 76 (suppl 9). https://acrabstracts.org/abstract/analysis-of-hospitalizations-of-adult-patients-with-kawasakis-disease-a-united-states-population-based-study/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2024

ACR Meeting Abstracts - https://acrabstracts.org/abstract/analysis-of-hospitalizations-of-adult-patients-with-kawasakis-disease-a-united-states-population-based-study/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology